Lidocain Panpharma (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing them in an inactive state. This inhibition prevents the rapid influx of sodium ions needed for depolarization, thereby stopping the initiation and propagation of nerve impulses and resulting in a reversible loss of sensation in the treated area.

The appropriate dose of Lidocain Panpharma is determined by the prescribing clinician based on the specific procedure, route of administration, patient age, weight, and overall health status. Healthcare professionals calculate the dose to stay within recommended maximum limits for safety.

Safety data for lidocaine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after evaluating the clinical situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for many short‑procedures. Compared with ester‑type agents like procaine, lidocaine has a lower risk of allergic reactions and a more predictable pharmacokinetic profile, though alternatives such as bupivacaine may offer longer lasting anesthesia.

Lidocain Panpharma should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations to maintain sterility and potency.

The product is supplied as a sterile solution for injection and may be administered intradermally, subcutaneously, or intravenously by a qualified healthcare professional. The route and technique are selected according to the intended procedure and patient-specific factors.

Serious risks include systemic toxicity manifesting as central nervous system symptoms (e.g., seizures, confusion), cardiovascular effects such as arrhythmias or severe hypotension, and rare allergic reactions that can progress to anaphylaxis. Prompt recognition and supportive management are essential if these events occur.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment should avoid using Lidocain Panpharma unless a specialist determines that benefits outweigh the risks.